This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Besponsa® (inotuzumab ozogamicin) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Besponsa® (inotuzumab ozogamicin)

Besponsa

BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).1

Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn More

Key Highlights

Click here to view the efficacy and safety data from the INO-VATE study

View data

Key data from the INO-VATE study

Listen to Dr. Anna Castleton discuss the key data for BESPONSA vs standard care from the INO-VATE study

Learn More

If you wish to discuss BESPONSA with one of our representatives, please click here to fill in a form so we may contact you at a convenient time.​​ 


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
PP-INO-GBR-0385. March 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No